Effect and tolerability of blonanserin in severe delusion with various types of dementia

Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D₂ receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D₃ receptor-blocking activities and weak 5-hydroxytryptamine-2C, α₁ -, histamine H₁ -, and muscarinic M₁ -blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia.